McDonald's Corporation

New York Stock Exchange
Back to all articles
Somewhat Bullish +35

McDonald's vs. Pfizer - The Better Retirement Stock Isn't the One You'd Guess

📊 McDonald's has raised its dividend for 49 consecutive years, including a 5% increase in October 2025, approaching Dividend King status.

💰 Pfizer offers a current yield near 7% ($1.72/share) compared to McDonald's yield of approximately 2.7% ($7.44/share).

⚠️ Pfizer's payout ratio exceeds 100% of trailing earnings, while McDonald's maintains a sustainable ratio near 59.5%.

📉 Pfizer faces significant risks from declining COVID business revenue and major patent expirations on drugs like Eliquis and Ibrance through 2030.

🏆 The article rates McDonald's as the better retirement stock due to its growing, well-covered payout and franchise stability.

📈 McDonald's shares are down about 12% year-to-date in 2026, while Pfizer has delivered a negative 42.2% total shareholder return over three years.

👨‍⚕️ Wall Street analysts remain split on Pfizer, with Argus rating it Buy for its GLP-1 pipeline and RBC Capital rating it Underperform due to revenue concerns.

Bullish Signals
  • McDonald's has increased its quarterly dividend by 5% in October 2025, marking the 49th straight annual increase.
  • McDonald's maintains a sustainable payout ratio near 59.5%, leaving ample room to continue raising dividends over time.
  • McDonald's generates steady free cash flow from its franchise-heavy business model, supporting long-term dividend reliability.
  • McDonald's has grown its dividend at a roughly 10% compound rate over the past five years.
Risk Factors
  • Pfizer's payout ratio exceeds 100% of trailing earnings, meaning the current dividend outstrips what the business recently earned.
  • Pfizer faces declining revenue from its COVID vaccine franchise and looming patent expirations on key drugs including Eliquis and Ibrance through 2030.
  • McDonald's shares are down about 12% year-to-date in 2026 due to earnings pressure from a softer low-income consumer environment.
  • Pfizer delivered a negative 42.2% total shareholder return over the three years ended December 2025 as the COVID franchise faded.
Full Analysis
McDonald's Corporation (NYSE:MCD) and Pfizer Inc. (NYSE:PFE) are compared as potential retirement stocks, with McDonald's favored for long-term reliability despite a lower current yield. While Pfizer offers a dividend yield near 7% driven by a stock price decline, McDonald's has increased its payout annually for nearly five decades, raising it by 5% in October 2025 to mark its 49th consecutive year of growth. McDonald's maintains a sustainable payout ratio of approximately 59.5% and generates steady free cash flow from its franchise-heavy business model. In contrast, Pfizer's high yield is supported by a payout ratio exceeding 100% of trailing earnings, indicating the dividend currently outstrips recent earnings. Management guidance suggests future adjusted EPS between $2.80 and $3.00 would cover the $1.72 annual dividend roughly 1.6 times. The article concludes that McDonald's is the superior core holding for retirees seeking income durability over decades, whereas Pfizer may serve only as a small satellite position due to risks from declining COVID revenue and looming patent expirations through 2030. Analysts remain divided on Pfizer, with some citing its GLP-1 pipeline while others warn of insurmountable revenue challenges.